Trade Hikma Pharmaceuticals PLC - HIK CFD
Add to favourite- Summary
- Historical Data
Spread | 0.42 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023925% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002007% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | GBP | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
Commission on trade | 0% |
Prev. Close | 19.56 |
Open | 19.5 |
1-Year Change | 11.62% |
Day's Range | 19.41 - 19.58 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 12, 2024 | 19.47 | 0.00 | 0.00% | 19.47 | 19.70 | 19.39 |
Dec 11, 2024 | 19.56 | 0.17 | 0.88% | 19.39 | 19.62 | 19.30 |
Dec 10, 2024 | 19.50 | -0.28 | -1.42% | 19.78 | 19.79 | 19.38 |
Dec 9, 2024 | 19.20 | -0.17 | -0.88% | 19.37 | 19.58 | 18.95 |
Dec 6, 2024 | 19.28 | 0.20 | 1.05% | 19.08 | 19.43 | 19.07 |
Dec 5, 2024 | 19.38 | -0.14 | -0.72% | 19.52 | 19.57 | 19.20 |
Dec 4, 2024 | 19.16 | -0.31 | -1.59% | 19.47 | 19.64 | 19.16 |
Dec 3, 2024 | 19.12 | -0.19 | -0.98% | 19.31 | 19.62 | 19.12 |
Dec 2, 2024 | 19.29 | -0.05 | -0.26% | 19.34 | 19.40 | 19.08 |
Nov 29, 2024 | 18.98 | -0.28 | -1.45% | 19.26 | 19.45 | 18.98 |
Nov 28, 2024 | 19.38 | -0.20 | -1.02% | 19.58 | 19.66 | 19.33 |
Nov 27, 2024 | 19.50 | -0.13 | -0.66% | 19.63 | 19.71 | 19.44 |
Nov 26, 2024 | 19.67 | -0.07 | -0.35% | 19.74 | 19.83 | 19.48 |
Nov 25, 2024 | 19.72 | 0.24 | 1.23% | 19.48 | 19.90 | 19.38 |
Nov 22, 2024 | 19.61 | 0.71 | 3.76% | 18.90 | 19.65 | 18.80 |
Nov 21, 2024 | 18.43 | -0.01 | -0.05% | 18.44 | 18.67 | 18.08 |
Nov 20, 2024 | 18.41 | 0.07 | 0.38% | 18.34 | 18.48 | 18.26 |
Nov 19, 2024 | 18.40 | 0.20 | 1.10% | 18.20 | 18.42 | 18.15 |
Nov 18, 2024 | 18.11 | 0.02 | 0.11% | 18.09 | 18.33 | 17.88 |
Nov 15, 2024 | 18.04 | 0.17 | 0.95% | 17.87 | 18.04 | 17.52 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Hikma Company profile
Discover the latest Hikma share price today with our comprehensive live chart.
Hikma Pharmaceuticals plc. (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. The company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics.
Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The Hikma’s branded division offers 499 products in 1,256 dosage strength. The most popular products are: Amoclan, Omnisef, Blopress and Suprax. The injectables division vendors 200 products in 379 dosage forms.
Hikma pharmaceuticals share price is set and traded on the London Stock Exchange (LSE) under the ticker symbol HIK. The company constitutes the FTSE 100 and FTSE 350 Indices.
Hikma made an initial public offering on 11 November 2005, and Hikma pharmaceuticals shares were listed for the first time, raising gross proceeds of $124 million.
Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, it became the first Arab company to export pharmaceutical products to the US.
The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquisitions helped Hikma to establish itself as the world’s leading provider in its industry.
In May 2014, Hikma Pharmaceuticals plc significantly increased its presence in the injected medicine market by purchasing assets from the US generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million.
The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma's position in a non-injectables business in the US market.
Hikma has been recognised as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a row: from 2014 to 2017.
According to Hikma’s latest earnings report, the company delivered strong growth in revenue and profit in 2019 with a group core revenue of $2,203 million (up 6 per cent) and operating profit of $508 million (up 10 per cent).
Follow the Hikma share price today with Capital.com to spot the best trading opportunities. Track all the ups and downs of the HIK stock price and stay on top of the latest price fluctuations with our live Hikma stock chart.
Industry: | Pharmaceuticals (NEC) |
1 New Burlington Place
LONDON
W1S 2HR
GB
News
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024Projected interest rates in 5 years:Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024Dogecoin price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
09:32, 4 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com